Iovance Biotherapeutics, Inc. (IOVA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of IOVA were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Iovance Biotherapeutics
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IOVA
291 funds and institutions reported IOVA shares worth $1.2B at the end of Q2 2026, about 65% of the company. The largest holder is BlackRock, Inc. with 8.3%.
Funds and institutions (13F) 65%Everyone else 35%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 36.96M | 8.28% | $154M | +19% |
| Mhr Fund Management LLC | 28.97M | 6.49% | $121M | No change |
| State Street Corp | 24.48M | 5.48% | $102M | +40% |
| Two Sigma Investments, LP | 19.01M | 4.26% | $79.1M | +39% |
| Vanguard Capital Management LLC | 18.20M | 4.08% | $75.7M | +10% |
| Vanguard Portfolio Management LLC | 14.39M | 3.22% | $59.9M | +23% |
| Geode Capital Management, LLC | 10.32M | 2.31% | $43M | +20% |
| Millennium Management LLC | 8.53M | 1.91% | $35.5M | -9% |
| Dimensional Fund Advisors LP | 6.46M | 1.45% | $26.9M | +144% |
| Palo Alto Investors LP | 5.30M | 1.19% | $22M | -17% |
| Goldman Sachs Group Inc | 5.10M | 1.14% | $21.2M | -42% |
| Nuveen, LLC | 5.00M | 1.12% | $20.8M | +36% |
| Bank of America Corp | 4.99M | 1.12% | $20.8M | -41% |
| Morgan Stanley | 4.99M | 1.12% | $20.7M | -20% |
| Jupiter Asset Management Ltd | 4.54M | 1.02% | $18.9M | – |
| Jane Street Group, LLC | 4.39M | 0.98% | $18.3M | +5% |
| Northern Trust Corp | 4.15M | 0.93% | $17.3M | +44% |
| AQR Capital Management LLC | 3.87M | 0.87% | $16.1M | +520% |
| Wells Fargo & Company | 3.25M | 0.73% | $13.5M | +57% |
| Charles Schwab Investment Management Inc | 3.22M | 0.72% | $13.4M | +16% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No IOVA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IOVA short interest
High short interest. 14.1% of IOVA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 39%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 65.19M IOVA shares were sold short, 14.1% of the shares outstanding, up 10.6% from the report before. At the average daily volume of 15.64M shares, buying them all back would take about 4.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 65.19M | 14.09% | +11% | 15.64M | 4.2 |
| Oct 15, 2026 | 58.93M | 13.01% | -9% | 13.31M | 4.4 |
| Sep 30, 2026 | 64.83M | 14.31% | -26% | 22.91M | 2.8 |
| Sep 15, 2026 | 87.13M | 19.23% | -1% | 11.73M | 7.4 |
| Aug 31, 2026 | 88.14M | 19.46% | -14% | 16.70M | 5.3 |
| Aug 14, 2026 | 102.94M | 22.73% | +3% | 21.51M | 4.8 |
| Jul 31, 2026 | 99.98M | 22.07% | +0% | 15.92M | 6.3 |
| Jul 15, 2026 | 99.89M | 22.37% | -1% | 16.90M | 5.9 |
| Jun 30, 2026 | 100.53M | 22.51% | -3% | 14.16M | 7.1 |
| Jun 15, 2026 | 103.49M | 23.18% | -1% | 13.11M | 7.9 |
| May 29, 2026 | 104.25M | 23.35% | -2% | 12.72M | 8.2 |
| May 15, 2026 | 106.61M | 23.88% | -7% | 17.78M | 6.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Iovance Biotherapeutics company events
Iovance Biotherapeutics filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 29, 2026AnnouncementIovance Biotherapeutics, Inc. issued a press release announcing updated results from Cohorts 1 and 2 of the Company’s Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung… Filing
- Oct 5, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
- Sep 29, 2026AnnouncementIovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance. Filing
- Aug 6, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
- Jun 10, 2026AnnouncementThe Company received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for previously treated advanced (metastatic or unresectable) melanoma. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 20, 2026LeadershipWendy Yarno, a member of the Board of Directors of Iovance Biotherapeutics, Inc., provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company’s annual meeting of stockholders currently anticipated to be held in June 2026. Filing
- Feb 24, 2026AnnouncementThe Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
- Jan 9, 2026AnnouncementIovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Iovance Biotherapeutics financials
Famous investors that hold IOVA
5 of the 50 well-known investors we track reported holding IOVA in their latest 13F filing. The largest position is Israel Englander's, worth $27.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.87M | $27.7M | 0.0% | -78% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.17M | $17.4M | 0.0% | -44% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.02M | $15.1M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 521,546 | $7.7M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 257,700 | $3.8M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IOVA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.8% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.8% |
Questions about Iovance Biotherapeutics, Inc. (IOVA) stock
Who owns the most IOVA stock?
The largest reported owner of Iovance Biotherapeutics, Inc. (IOVA) is BlackRock, Inc., with 8.3% of the company. In total, 291 funds and institutions reported holding IOVA at the end of Q2 2026, together about 65% of the shares. See the largest owners.
Are IOVA insiders buying or selling?
No IOVA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in IOVA?
As of Oct 30, 2026, 65.19M IOVA shares were sold short, 14.1% of the shares outstanding, up 10.6% from the report before. At the average daily volume of 15.64M shares, buying them all back would take about 4.2 trading days (days to cover). See the history.
Which famous investors hold IOVA?
5 of the 50 well-known investors we track reported IOVA in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $27.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.